ClinicalTrials.gg
WithdrawnNCT01164540Du LacUpdated Dec 10, 2010

Study on the Effect of Rosuvastatin Treatment on the Prevention of Thrombosis in Patients With Previous Thrombosis

A Phase 3 interventional study of Rosuvastatin (AZD4522) and Placebo in Venous Thrombosis and Pulmonary Embolism, sponsored by AstraZeneca. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-12-10.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Due to discussion regarding the design of the study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study evaluates whether treatment with rosuvastatin on top of standard anti-coagulant treatment will decrease the risk of recurrent venous thromboembolism and arterial thromboembolic events in patients with previous deep vein thrombosis or pulmonary embolism.

02

Conditions studied

  • Venous Thrombosis
  • Pulmonary Embolism

Keywords

  • Deep venous thrombosis
  • Pulmonary embolism
  • rosuvastatin treatment
03

In context

Venous Thrombosis

785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.

This study's planned enrollment of 3,000 is above the median of 152 across 477 interventional studies indexed under Venous Thrombosis.

Browse Venous Thrombosis studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed .
  • Patients with venous thromboembolism who are treated with anti-coagulant according to the current guidelines

Exclusion criteria

Exclusion Criteria:

  • Patients in need of or already treated with lipid lowering drugs
  • Active liver or kidney disease or dysfunction or muscle disorders
  • Unstable medical or psychological condition that interferes with study participation
  • Pregnant woman or woman with who are not willing to use
  • History of statin-related muscular pain, or to statins
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
3,000 participants (estimated)

Study arms

  • Experimental
    1

    Oral Treatment

    Drug: Rosuvastatin (AZD4522)

  • Placebo comparator
    2

    Oral treatment

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Any event of venous thromboembolism (i.e. Deep Vein Thrombosis (DVT) and/or fatal or non-fatal Pulmonary Embolism(PE))

    Time frame: Time to first occurrence in the overall treatment period, with a median treatment period of 9,5 months

Secondary outcomes

  1. All cause mortality

    Time frame: Time to occurrence in the overall treatment period, with a median treatment period of 9,5 months

  2. Any event of the composite of venous thromboembolism or arterial thromboembolism/major adverse cardiovascular event (MACE)

    Time to first occurrence in the overall treatment period and during the "on (VKA)" treatment period, with an estimated average "on (VKA) treatment period" of 6 months

    Time frame: Time to first occurrence in the overall treatment period and during the "on Vitamin K Antagonist (VKA)" treatment period

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2010
First posted
Jul 16, 2010
Start
Feb 2011
Primary completionEst.
Mar 2013
CompletionEst.
Mar 2013
Last update
Dec 10, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01164540
Lead sponsor
AstraZeneca
First posted
Jul 16, 2010
Start date
Feb 2011
Primary completion
Mar 2013 (estimated)
Completion
Mar 2013 (estimated)
Last update
Dec 10, 2010

Study contacts

H. R. Büller, MD, PhD
principal investigator · Academic Medical Centre
Michael Cressman, MD
study director · AstraZeneca

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion